CELC Quote, Financials, Valuation and Earnings

Arrowhead Pharmaceuticals, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of 10.7%. Celcuity, Inc.'s return on equity of -158.5% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.

Celcuity, Inc. has a consensus price target of $116.70, signalling upside risk potential of 4.47%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.36 which suggests that it could grow by 28.6%. Given that Arrowhead Pharmaceuticals, Inc. has higher upside potential than Celcuity, Inc., analysts believe Arrowhead Pharmaceuticals, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.382, which suggesting that the stock is 61.833% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.681%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. Celcuity, Inc.'s net income of -$43.8M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 41.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus 7.97x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cogent Biosciences, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of --. Celcuity, Inc.'s return on equity of -158.5% beat Cogent Biosciences, Inc.'s return on equity of -104.81%.

Celcuity, Inc. has a consensus price target of $116.70, signalling upside risk potential of 4.47%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $53.83 which suggests that it could grow by 38.57%. Given that Cogent Biosciences, Inc. has higher upside potential than Celcuity, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.382, which suggesting that the stock is 61.833% less volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.468, suggesting its less volatile than the S&P 500 by 53.231%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Cogent Biosciences, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is higher than Cogent Biosciences, Inc.'s net income of -$102.5M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Praxis Precision Medicines, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of -786.27%. Celcuity, Inc.'s return on equity of -158.5% beat Praxis Precision Medicines, Inc.'s return on equity of -60.4%.

Celcuity, Inc. has a consensus price target of $116.70, signalling upside risk potential of 4.47%. On the other hand Praxis Precision Medicines, Inc. has an analysts' consensus of $600.71 which suggests that it could grow by 78.38%. Given that Praxis Precision Medicines, Inc. has higher upside potential than Celcuity, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.382, which suggesting that the stock is 61.833% less volatile than S&P 500. In comparison Praxis Precision Medicines, Inc. has a beta of 2.859, suggesting its more volatile than the S&P 500 by 185.918%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Praxis Precision Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Praxis Precision Medicines, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Praxis Precision Medicines, Inc. quarterly revenues of --. Celcuity, Inc.'s net income of -$43.8M is higher than Praxis Precision Medicines, Inc.'s net income of -$88.9M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Praxis Precision Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus 930.95x for Praxis Precision Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rhythm Pharmaceuticals, Inc. has a net margin of -- compared to Celcuity, Inc.'s net margin of -82.97%. Celcuity, Inc.'s return on equity of -158.5% beat Rhythm Pharmaceuticals, Inc.'s return on equity of -310.34%.

Celcuity, Inc. has a consensus price target of $116.70, signalling upside risk potential of 4.47%. On the other hand Rhythm Pharmaceuticals, Inc. has an analysts' consensus of $140.67 which suggests that it could grow by 52.77%. Given that Rhythm Pharmaceuticals, Inc. has higher upside potential than Celcuity, Inc., analysts believe Rhythm Pharmaceuticals, Inc. is more attractive than Celcuity, Inc..

Celcuity, Inc. has a beta of 0.382, which suggesting that the stock is 61.833% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals, Inc. has a beta of 2.058, suggesting its more volatile than the S&P 500 by 105.795%.

Celcuity, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Celcuity, Inc. pays -- of its earnings as a dividend. Rhythm Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Celcuity, Inc. quarterly revenues are --, which are smaller than Rhythm Pharmaceuticals, Inc. quarterly revenues of $57.3M. Celcuity, Inc.'s net income of -$43.8M is higher than Rhythm Pharmaceuticals, Inc.'s net income of -$47.5M. Notably, Celcuity, Inc.'s price-to-earnings ratio is -- while Rhythm Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Celcuity, Inc. is -- versus 31.75x for Rhythm Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.